跳到主要內容

Frost Phillip MD Et Al 的 Form 4 申報

Opko Health, Inc.OPK,2024/1/8 申報

申報編號
0000950170-24-002735
申報時間
2024/1/8 08:54 ET
交易日
2024/1/4-1/5
申報延遲
4 天
10b5-1 計畫
沒有勾選

這份申報列了 1 筆非衍生性交易、2 筆衍生性交易。公開市場買進合計 $134.5 萬。交易後 4 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Frost Phillip MD Et AlCIK 0000898860董事、高階主管(執行長、董事長)、持股 10% 以上大股東
Frost Gamma Investments TrustCIK 0001380896持股 10% 以上大股東

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2024/1/5Common StockP買進取得+1,500,000$0.8964F1+$1,344,600203,456,694間接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2024/1/45% Convertible Notes due 2025D交回公司處分––F4––間接
2024/1/43.75% Convertible Notes due 2029A公司授予取得––F6––間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8537 to $0.9475, inclusive. The reporting person undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

表 I 有 1 筆交易的價格引用這則附註。

F4

The 5% Convertible Promissory Notes due 2025 were originally entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of such original notes, plus unpaid interest, into shares of the Company's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. Pursuant to an amendment on February 10, 2023, the maturity date was extended to January 31, 2025, which amendment also reset the conversion price to the 10 day volume weighted average price immediately preceding the date of such amendment, plus a 25% conversion premium, or $1.66.

表 II 有 1 筆交易的價格引用這則附註。

F6

The reporting person entered into a Convertible Note Purchase Agreement with the Company on January 4, 2024, pursuant to which the reporting person disposed of $25,000,000 aggregate principal amount of 5% Convertible Promissory Notes due 2025, and accrued but unpaid interest thereon, in exchange for $32,308,000 aggregate principal amount of the Company's 3.75% Convertible Senior Notes due 2029 in a private placement.

表 II 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)